N-[2-(2-hydroxyethoxy)-ethyl]-2-(2,4,6-trichlorophenylamino)benzenesulfonamide | 1159282-06-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2-(2-hydroxyethoxy)-ethyl]-2-(2,4,6-trichlorophenylamino)benzenesulfonamide
• 英文别名: N-[2-(2-hydroxyethoxy)ethyl]-2-(2,4,6-trichloroanilino)benzenesulfonamide
• CAS: 1159282-06-0
• 化学式: C₁₆H₁₇Cl₃N₂O₄S
• 分子量: 439.747
• InChiKey: SYAIRLOIBVYMEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  96
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Heat shock protein 90 inhibitors
  申请人：Blagg Brian

  公开号：US20060089495A1

  公开（公告）日：2006-04-27

  Novel compounds useful for inhibiting the 90 kDa heat shock proteins containing a quinone-like moiety and a di-hydroxy phenol like moiety, similar to geldanamycin and radicicol.

  新型化合物对抑制含有类似醌类结构和二羟基酚类结构的90千道尔顿热休克蛋白具有用途，类似于格尔德霉素和拉迪考尔。
• POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF
  申请人：Edwards Simon David

  公开号：US20120065270A1

  公开（公告）日：2012-03-15

  Compounds of formula (I) and pharmacologically acceptable salts and pro-drugs wherein: Ar 1 and Ar 2 =aryl or heteroaryl; a=0 to 5; R 1 =alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monalkylamino, dialkylamino, nitro, acylamino, alkoxycarbonylamino, alkylsulphonyl, alkylsulphonylamino and cyano and, where a is >1, each R 1 is the same or different; b=0 to 5; R 2 =alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monalkylamino, dialkylamino, nitro, acylamino, alkoxycarbonylamino, alkylsulphonyl, alkylsulphonylamino and cyano and where b is >1, each R 2 is the same or different; V=(CR 3a R 3b ) p SO 2 N(R 3b )X and (CR 3a R 3b ) p N(R 3b )SO 2 (X); W=NR 4a , O, S, S═O, SO 2 and C(R 4a R 4b ) 2 ; X=hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, aryloxyalkyl, polyalkylene glycol residues, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl and alkyl groups substituted with ≧1 NR8R9 groups wherein R8 and R9+nitrogen atom form a saturated or partially unsaturated heterocyclic group which is optionally further substituted by ≧1 substituents selected from alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, nitro, amino, monoalkylamino, dialkylamino and hydroxyl; Y and Z each ═(CR 5a R 5b ) n1 , C═O, SO 2 , C(═O)NR 5a , C(═O)NR 5a SO 2 or C═O(R 5a R 5b ) n2 ; R 3a , R 3b , R 4a , R 4b , R 5a and R 5b each=hydrogen, alkyl, cycloalkyl, aryl or heteroaryl; n1 and n2 each =0 to 2; and p=0 to 2; are excellent selective modulators of potassium ion flux through KCNQ2, KCNQ3 and/or KCNQ2/3 channels, making them of use in treating and preventing a number of conditions including pain and lower urinary tract disorders.

  公式（I）的化合物及其药理学上可接受的盐和前药，其中： Ar1和Ar2 = 芳基或杂环芳基; a = 0到5; R1 = 烷基，卤素，卤代烷基，烷氧基，烷氧羰基，羧基，羟基，氨基，单烷基氨基，二烷基氨基，硝基，酰胺基，烷氧羰基氨基，烷基磺酰基，烷基磺酰胺基和氰基，当a> 1时，每个R1相同或不同; b = 0到5; R2 = 烷基，卤素，卤代烷基，烷氧基，烷氧羰基，羧基，羟基，氨基，单烷基氨基，二烷基氨基，硝基，酰胺基，烷氧羰基氨基，烷基磺酰基，烷基磺酰胺基和氰基，当b> 1时，每个R2相同或不同; V =（CR3aR3b）pSO2N（R3b）X和（CR3aR3b）pN（R3b）SO2（X）; W = NR4a，O，S，S═O，SO2和C（R4aR4b）2; X = 羟基烷基，烷氧基烷基，卤代烷氧基烷基，芳氧基烷基，聚烷基乙二醇残基，氨基烷基，单烷基氨基烷基，二烷基氨基烷基和被≧1个NR8R9基取代的烷基，其中R8和R9 +氮原子形成饱和或部分不饱和的杂环基团，该杂环基团可以选择地进一步取代为≧1个取代基，所选取代基从烷基，卤素，卤代烷基，烷氧基，烷氧羰基，羧基，硝基，氨基，单烷基氨基，二烷基氨基和羟基中选择; Y和Z各自═（CR5aR5b）n1，C═O，SO2，C（═O）NR5a，C（═O）NR5aSO2或C═O（R5aR5b）n2; R3a，R3b，R4a，R4b，R5a和R5b各自为氢，烷基，环烷基，芳基或杂环芳基; n1和n2各自= 0到2; p = 0到2; 它们是钾离子通量通过KCNQ2，KCNQ3和/或KCNQ2/3通道的优异选择性调节剂，因此可用于治疗和预防包括疼痛和下尿路障碍在内的多种疾病。
• Vitamin-Receptor Binding Drug Delivery Conjugates
  申请人：Endocyte, Inc.

  公开号：US20160220694A1

  公开（公告）日：2016-08-04

  The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.

  该发明描述了一种维生素受体结合药物传递共轭物及其制备方法。药物传递共轭物由维生素受体结合基团、双价连接剂（L）和药物组成。维生素受体结合基团包括维生素、维生素受体结合类似物及其衍生物，药物包括类似物及其衍生物。维生素受体结合基团与双价连接剂共价连接，药物或其类似物或衍生物与双价连接剂共价连接，其中双价连接剂（L）包括间隔连接剂、可释放连接剂和杂原子连接剂以及其组合。还描述了利用该药物传递共轭物消除病原细胞群的方法和药物组合物。
• METHOD AND CATALYST FOR SYNTHESISING AZIRIDINE
  申请人：University of East Anglia

  公开号：US20150166478A1

  公开（公告）日：2015-06-18

  The present invention relates to methods of synthesising aziridines including isotopically labelled aziridines, said methods comprising contacting an imine or one or more precursors thereof with a diazo compound in the presence of a phosphoramide or a phosphoramide-derived catalyst. The present invention also relates to aziridines, modified aziridines and aziridine-derived compounds preparable by the aforementioned methods, and to phosphoramide or phosphoramide-derived catalysts suitable for use in such methods.

  本发明涉及合成环氧乙烷的方法，包括同位素标记的环氧乙烷，所述方法包括将亚胺或其一个或多个前体与重氮化合物在磷酰胺或磷酰胺衍生的催化剂存在下接触。本发明还涉及通过上述方法制备的环氧乙烷、改性环氧乙烷和环氧乙烷衍生化合物，以及适用于这种方法的磷酰胺或磷酰胺衍生的催化剂。
• [EN] METHOD AND CATALYST FOR SYNTHESISING AZIRIDINE<br/>[FR] PROCÉDÉ ET CATALYSEUR POUR LA SYNTHÈSE D'AZIRIDINE
  申请人：UNIV EAST ANGLIA

  公开号：WO2013179052A1

  公开（公告）日：2013-12-05

  The present invention relates to methods of synthesising aziridines including isotopically labelled aziridines, said methods comprising contacting an imine or one or more precursors thereof with a diazo compound in the presence of a phosphoramide or a phosphoramide-derived catalyst. The present invention also relates to aziridines, modified aziridines and aziridine-derived compounds preparable by the aforementioned methods, and to phosphoramide or phosphoramide-derived catalysts suitable for use in such methods.

  本发明涉及一种合成环丙胺的方法，包括同位素标记的环丙胺，所述方法包括在磷酰胺或磷酰胺衍生的催化剂存在下，将亚胺或其一个或多个前体与重氮化合物接触。本发明还涉及通过上述方法可制备的环丙胺、改性环丙胺和环丙胺衍生化合物，以及适用于此类方法的磷酰胺或磷酰胺衍生的催化剂。